The stock of Viatris (NAS:VTRS, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $13.785 per share and the market cap of $16.7 billion, Viatris stock is estimated to be fairly valued. GF Value for Viatris is shown in the chart below.
Because Viatris is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which is estimated to grow 11.80% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. Viatris has a cash-to-debt ratio of 0.04, which is in the bottom 10% of the companies in Drug Manufacturers industry. GuruFocus ranks the overall financial strength of Viatris at 3 out of 10, which indicates that the financial strength of Viatris is poor. This is the debt and cash of Viatris over the past years:
Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Viatris has been profitable 9 over the past 10 years. Over the past twelve months, the company had a revenue of $13.8 billion and loss of $2.01 a share. Its operating margin is -3.87%, which ranks in the middle range of the companies in Drug Manufacturers industry. Overall, the profitability of Viatris is ranked 6 out of 10, which indicates fair profitability. This is the revenue and net income of Viatris over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company’s stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Viatris is -3.6%, which ranks worse than 76% of the companies in Drug Manufacturers industry. The 3-year average EBITDA growth rate is -18.1%, which ranks worse than 81% of the companies in Drug Manufacturers industry.
Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Viatris’s return on invested capital is -1.98, and its cost of capital is 5.45. The historical ROIC vs WACC comparison of Viatris is shown below:
In conclusion, the stock of Viatris (NAS:VTRS, 30-year Financials) shows every sign of being fairly valued. The company's financial condition is poor and its profitability is fair. Its growth ranks worse than 81% of the companies in Drug Manufacturers industry. To learn more about Viatris stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
